Who
Alexis Borisy
Director
Company insider
Files Form 4 as: Director, Revolution Medicines; Director, Parabilis Medicines; Director, Relay Therapeutics; Director, Blueprint Medicines; Director, Tango Therapeutics; Executive Chairman, EQRx; Director, Opko Health; Director, Dianthus Therapeutics.
In numbers
- Trades disclosed
- 159
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $26.0M
- Companies
- 11
- Companies where not an officer
- 9
- First trade
- 26 Jan 2006
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code A | —1,191 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,127 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,127 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code A | —1,191 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PBLS Parabilis MedicinesBiotechnology | SEC FORM 4 Code C | —105,414 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PBLS Parabilis Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code C | —162,221 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PBLS Parabilis Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code C | —162,221 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PBLS Parabilis MedicinesBiotechnology | SEC FORM 4 Code C | —105,414 | filing |
| 9 Jun 2026filed 11 Jun 2026 | PBLS Parabilis Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,215 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | PBLS Parabilis Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,215 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,947 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,947 at $0.00 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —7,500 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —4,875 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —4,500 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —4,500 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —5,300 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —5,300 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —4,570 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicines | SEC FORM 4 Code D | —3,902 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
Related people
Nobody else traded the same names lately.